





# U.S. President's Malaria Initiative



# Cost and Effectiveness Analysis of "Strategically Packaging" Malaria Interventions - Evidence from a Retrospective Analysis in Senegal

#### Sophie Faye<sup>1</sup>; Altea Cico<sup>1</sup>; Alioune Badara Gueye<sup>2</sup>; Elaine Baruwa<sup>1</sup>; Benjamin Johns<sup>1</sup>; Martin Alilio<sup>3</sup>


<sup>1</sup>Abt Associates, USA; <sup>2</sup>Senegal National Malaria Control Program (PNLP); <sup>3</sup>U.S. President's Malaria Initiative, U.S. Agency for International Development, USA

# Background

- Resources for malaria control and elimination interventions are limited
- Cost-effectiveness data is necessary for decision-making and planning
- Lack of cost-effectiveness data for intervention combinations or "packages"

Senegal Malaria control packages

- 1. SUFI (Scale Up For Impact) only: LLINs + IPTp + RDTs + ACTs + PECADOM (community-based case management)
- 2. SUFI + Seasonal Malaria Chemoprevention (SMC)
- 3. SUFI + Indoor Residual Spraying (IRS)
- 4. SUFI + SMC + IRS
- 5. SUFI + Reactive Case Investigation (Focal Screen and Treat and Mass Screen and Treat)



(Source: National Malaria Control Strategic Plan 2016-2020)

# Objectives

- Estimate cost-effectiveness ratios (CER) for different packages of malaria interventions in Senegal using routine data, as opposed to modelling
- Utilize results to identify potential efficiency gains and to draw lessons as malaria epidemiology evolves in Senegal



# Data

- Retrospective analysis of 2013-2014: first two years that all packages were occurring
- District level data for Senegal's 76 districts (incidence, mortality, intervention coverage, outputs and costs)
- Costing analysis: only direct financial implementation costs
- Coverage/output and cost data for interventions obtained from NMCP or implementing partners

## Methods

- Total annual costs estimated using top down and bottom up approaches
- Intervention costs aggregated to obtain package costs
- Package effectiveness measured in disability-adjusted life years (DALYs) averted for the study period
- CER: Cumulative costs of a package in its area of implementation divided by cumulative DALYs averted

**Implementation** of a Package

**Decreased** Malaria **Incidence** and **Mortality** 

**Decreased** Disability Adjusted Life Years (DALY)

Increased **Effectiveness** 

### Results

#### Total Costs of Interventions/Packages

- SUFI only had the highest total cost; LLINs accounted for almost 80 percent of total cost
- SUFI (LLINs, IPTp, case management, PECADOM) is the largest component of all other packages, except those with IRS
- Seasonal malaria chemoprevention (SMC) accounts for almost half of total cost of SUFI+SMC package

## Total annual cost of packages (USD) SUFI+RCI (4 districts) SUFI+IRS+SMC (2 districts) SUFI+SMC (14 districts) SUFI+IRS (2 districts) SUFI-only (54 districts) 2,000,000 3,000,000 4,000,000 5,000,000 6,000,000

#### Unit Costs of Interventions/Packages

- Lower unit costs of prevention-related interventions, vs. treatment-related
- Indoor residual spraying (IRS) had highest unit cost of preventive interventions, reactive case investigation (RCI) highest among treatment interventions

#### Unit Cost per Intervention

Intervention Type	Unit cost per beneficiary (USD)	Intervention Coverage			
Prevention					
IRS	3.57	98.3%			
SMC	2.38	97.2%			
LLIN	0.91	57.8%			
IPT <sub>P</sub>	0.56	66.3%			
	Treatment				
RCI	9.82	NA			
PECADOM	9.25	NA			
Case management	1.43	NA			

Packages with IRS had highest unit cost

■ PECADOM ■ Case management ■ IRS ■ SMC ■ RCI

SUFI only had lowest unit cost, followed by SUFI+RCI

#### Unit Costs by package

Packages	Unit cost per capita* (USD)
SUFI+SMC+IRS	4.55
SUFI +IRS	4.19
SUFI +SMC	1.52
SUFI +RCI	1.09
SUFI only	0.54

#### \*Unit cost is calculated using the population of the areas where a package is implemented

#### Package Effectiveness

- Decrease in malaria incidence and mortality over the study period
- Packages with SMC had largest decrease in incidence
- Packages with IRS had largest decrease in mortality

#### Malaria burden changes over study period by package

ridialia barden changes over study period by package					
Package	Number of Districts	Change in Average Incidence Rate 2013-2014	Change in Average Mortality Rate 2013-2014		
SUFI only	54	-31.9%	-33.4%		
SUFI + IRS	2	-37.6%	-78.8%		
SUFI + SMC	14	-52.6%	-73.7%		
SUFI + SMC + IRS	2	-52.2%	-88.9%		
SUFI + RCI	4	-52.0%	-7.6%		

\*Incidence, mortality, and DALYs rates are respectively in number per 1,000 population. The comparison is over the period 2013 -2014.

# Package Cost Effectiveness

- Per WHO guidelines, all packages were "very cost effective," meaning CER was less than country GDP per capita of \$1,067 in 2014
- Exception: SUFI+RCI package is "cost effective," meaning CER less than 3 times the GDP per capita
- Relative to other packages, SUFI+SMC is most cost effective, SUFI+RCI is least cost effective

#### Cost effectiveness ratios by malaria package

	Packages	Cost per DALY averted (USD)	Sensitivity analysis*	
			Lower value	<b>Upper value</b>
SS	SUFI only	133	104	182
	SUFI+IRS	591	463	816
	SUFI+SMC	81	65	106
	SUFI+SMC+IRS	275	219	367
	SUFI+RCI	1,349	985	2,141

For the number of DALYs averted, we calculated extreme values as well as the mid-point for sensitivity analysis

### Discussion

- Deploying interventions in packages based on incidence could be recommended to other countries
- All packages were "cost effective" based on WHO threshold
- Not advisable to compare cost-effectiveness of elimination packages to control
- SMC + IRS more cost effective than IRS only
- Efficiency gains possible with increased LLIN and IPTp coverage
- Strong surveillance and outcome monitoring systems needed for country-specific studies

Thank you to our collaborators without whom this study would not have been possible:

Senegal's National Malaria Control Program and Ministry of Health;

■ Pharmacie Nationale d'Approvisionnement (PNA), the Institut de Recherche pour le Développement (IRD), and the Institut de Santé et Développement (ISED) at Université Cheikh Anta Diop;

■ IntraHealth, PATH/MACEPA, ChildFund, ADEMAS, Abt Associates/AIRS and Abt Associates/RSS;

■ Local research coordinator Moussa Dieng



